BIOSIMILAR CONTRACT MANUFACTURING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Regional Analysis

To learn more about this report, Request sample copy

North America Biosimilar Contract Manufacturing Market Trends

North America dominates the biosimilar contract manufacturing market with an estimated share of 37.2% in 2024. This can be attributed to factors such as the strong presence of contract manufacturing organizations CMOs and the presence of well-established biopharmaceutical companies. Countries, such as the U.S. and Canada, have significantly invested in developing their biopharmaceutical ecosystem over the years through supportive regulations and funding for R&D. Several major biologics manufacturers in the region, such as Pfizer, also contribute to the market growth through their partnerships with CMOs for outsourcing biosimilar manufacturing needs.

Asia Pacific Biosimilar Contract Manufacturing Market Trends

The Asia Pacific region exhibits the fastest growth with an estimated share of 27.7% in 2024 and is expected to emerge as an important player driven by rising investments from governments and private sector to bolster local biosimilar drug development and manufacturing capabilities. Countries such as China, India, and South Korea offer strategic advantages in terms of skilled workforce, infrastructure development through initiatives such as special economic zones, and favorable business environment which have helped attract biopharmaceutical companies seeking to expand operations overseas.

Biosimilar Contract Manufacturing Market Outlook for Key Countries

U.S. Biosimilar Contract Manufacturing Market Trends

The U.S. biosimilar contract manufacturing market is poised for significant growth in the coming years. The U.S. government's initiatives to lower healthcare costs, including policies promoting the adoption of biosimilars, have fueled demand. The increasing acceptance of biosimilars in the U.S., coupled with the expiration of numerous biologic patents, has encouraged pharmaceutical companies to outsource manufacturing to contract manufacturers. In May 2024, Boehringer Ingelheim partnered with Quallent Pharmaceuticals to expand access to its citrate-free adalimumab-adbm, a biosimilar to Humira, in the U.S. This collaboration aims to increase availability for patients with chronic inflammatory diseases, reduce healthcare costs, and promote biosimilar adoption in the U.S. biosimilar contract manufacturing market.

Canada Biosimilar Contract Manufacturing Market Trends

Canada biosimilar contract manufacturing industry is growing steadily due to rising new product launches & approvals. For instance, in January 2022, Health Canada approved SIMLANDI, a biosimilar to Humira developed by Alvotech, a global biopharmaceutical company and marketed by JAMP Pharma, a Canada-based pharmaceutical company. It is the first high-strength version of this medicine available in Canada, similar to the popular formulations used in the U.S.

Germany Biosimilar Contract Manufacturing Market Trends

Germany's strong biopharmaceutical infrastructure supports biosimilar development. The government’s investment in healthcare innovation, including a USD 3.15 billion funding initiative announced in January 2024, is expected to boost biosimilar production capabilities, as reported by the Federal Ministry of Education and Research (BMBF).

India Biosimilar Contract Manufacturing Market Trends

India is a key player in the biosimilar manufacturing sector, leveraging cost advantages. The "Make in India" initiative, launched in March 2023, aims to enhance local manufacturing capabilities and attract global partnerships in biosimilars, as stated by the government of India.